Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review

Date: May 9, 2019
Pages: 50
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: HDE79976B42EN
Leaflet:

Download PDF Leaflet

Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review
Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Heron Therapeutics Inc (Heron), formerly A.P. Pharma, Inc., is a biotechnology company that uses proprietary polymer-based drug delivery platform to develop novel, patient-focused drugs for patients suffering from cancer and pain. Its proprietary Biochronomer technology is a polymer-based drug delivery platform, which improves the therapeutic profile of injectable pharmaceuticals. The company's first commercial product, Sustol is an extended-release injection indicated in combination with other antiemetics in adults for the prevention of nausea and vomiting due tomoderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Heron's developmental pipeline includes HTX-011 for post-operative pain management and Cinvanti (HTX-019) for chemotherapy-induced nausea and vomiting (CINV) prevention. Heron is headquartered in San Diego, California, the US.

Heron Therapeutics Inc Key Recent Developments

Feb 22,2019 Heron Therapeutics announces financial results for the three and twelve months ended December 31, 2018 and recent corporate progress
Feb 05,2019 Heron Therapeutics announces Retirement of Robert Rosen as President
Jan 07,2019 Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
Jan 04,2019 Latest News Tragara Pharmaceuticals Appoints Scott Megaffin as Chief Executive Officer and Changes Name to Adastra Pharmaceuticals Thu, 03 Jan 2019 12:59:06 GMT Company Well-Positioned for Next Phase of Clinical Advancement with Lead Oral Drug Candidate,

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY

Heron Therapeutics Inc - Key Facts
Heron Therapeutics Inc - Key Employees
Heron Therapeutics Inc - Key Employee Biographies
Heron Therapeutics Inc - Major Products and Services
Heron Therapeutics Inc - History
Heron Therapeutics Inc - Company Statement
Heron Therapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Heron Therapeutics Inc - Business Description
Product Category: Cinvanti
Overview
Product Category: HTX-011
Overview
Product Category: Sustol
Overview
R&D Overview
Heron Therapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Heron Therapeutics Inc - Strengths
Heron Therapeutics Inc - Weaknesses
Heron Therapeutics Inc - Opportunities
Heron Therapeutics Inc - Threats
Heron Therapeutics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Heron Therapeutics Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 22, 2019: Heron Therapeutics announces financial results for the three and twelve months ended December 31, 2018 and recent corporate progress
Feb 05, 2019: Heron Therapeutics announces Retirement of Robert Rosen as President
Jan 07, 2019: Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises
Jan 04, 2019: Latest News Tragara Pharmaceuticals Appoints Scott Megaffin as Chief Executive Officer and Changes Name to Adastra Pharmaceuticals Thu, 03 Jan 2019 12:59:06 GMT Company Well-Positioned for Next Phase of Clinical Advancement with Lead Oral Drug Candidate,
Oct 31, 2018: Heron Announces FDA Submission of HTX-011 NDA for Postoperative Pain Management
Sep 30, 2018: Heron Therapeutics announces financial results for the three and nine months ended September 30, 2018 and recent corporate progress
Aug 08, 2018: Heron Therapeutics announces financial results for the three and six months ended june 30, 2018 and recent corporate progress
May 10, 2018: Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress
Feb 27, 2018: Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress
Jan 08, 2018: Heron Therapeutics Highlights Progress in CINV and Pain Management Franchises

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Heron Therapeutics Inc, Key Facts
Heron Therapeutics Inc, Key Employees
Heron Therapeutics Inc, Key Employee Biographies
Heron Therapeutics Inc, Major Products and Services
Heron Therapeutics Inc, History
Heron Therapeutics Inc, Other Locations
Heron Therapeutics Inc, Key Competitors
Heron Therapeutics Inc, Ratios based on current share price
Heron Therapeutics Inc, Annual Ratios
Heron Therapeutics Inc, Annual Ratios (Cont...1)
Heron Therapeutics Inc, Interim Ratios
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Heron Therapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Heron Therapeutics Inc, Performance Chart (2014 - 2018)
Heron Therapeutics Inc, Ratio Charts
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Heron Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

ProStrakan Group plc
Pacira Pharmaceuticals Inc
Hospira Inc
GlaxoSmithKline Plc
F. Hoffmann-La Roche Ltd
Eisai Co Ltd
Skip to top


Ask Your Question

Heron Therapeutics Inc (HRTX) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: